That’s the question the Multidisciplinary Association of Psychedelic Studies (MAPS) has been attempting to answer for years with their MDMA-assisted psychotherapy trials.

For those who came for the MDMA, but don’t know much about Post-Traumatic Stress Disorder (PTSD), WebMD defines it as…

A mental health condition that’s triggered by a terrifying event — either experiencing it or witnessing it. Symptoms may include flashbacks, nightmares and severe anxiety, as well as uncontrollable thoughts about the event.

It’s been described as being permanently locked in the fight-or-flight response state, with perceived threats causing your stress hormones to spike higher than normal and stay there for extended periods of time (many people are locked in this state for years).

I first heard of this condition after getting stabbed at 15 years old and becoming severely anxious and depressed in the coming years. Six months after this traumatic incident, I attempted to take my own life by slitting my wrist with a straight-edged razor. I’d been in therapy and on anti-depressants for a while at that point, but I still didn’t feel like I was getting any better. The therapy sessions were more about me trying to prove to myself that everything was okay than actually opening up about the terrifying thoughts and fears swirling around in my head. I was worried if I told my therapist that when I was driving I was afraid every car that was behind me for more than half a mile was following me I’d be labeled a paranoid schizophrenic and thrown in the psyche ward. Large crowds scared me. New people scared me. Even seemingly unrelated anxieties, like those of being in the presence of a girl I liked, would trigger intense emotions that seemed unbearable.

I was suffering from PTSD. I continued to suffer for years until time and enough self-help books to fill a library began to slowly wither away the constant worries I’d been plagued with. It was hell, and many people are stuck in that hell right now. They’re soldiers, police officers, and sexual assault victims. They’re your neighbors, co-workers, and family. They probably never speak of the pain they’re in because it hurts too much. They need help, but have tried other therapies and medications and nothing seems to work.

Enter MDMA.

For anyone that hasn’t been to Coachella in the last decade, MDMA can be thought of as Ecstasy or Molly, although the latter two drugs are very often cut with other dangerous chemicals making them much less safe. However, the effects these drugs have on the brain are nearly the same. Each increase the activity of three brain chemicals…

When combined, these chemicals work together to increase energy and happiness (dopamine), enhance formation and retrieval of memories and focus attention (norepinephrine), and promote a sense of well-being and empathy (serotonin).

The idea behind using MDMA in psychotherapy was that the feelings produced by the drug would greatly enhance the value the sufferer received during their therapy session, so much so that just two to three eight-hour sessions could produce long-lasting results. And that’s exactly what MAPS has observed in the trials they’ve undertaken to get the drug approved by the FDA. The completed studies have been limited mainly to combat veterans, sexual assault victims, and police officers and firefighters who had not responded to other treatments. On average, these people had been suffering from treatment-resistant PTSD for nearly 18 years. Cut to one year after their MDMA-assisted psychotherapy sessions and 68% of the participants in the Phase 2 trials no longer met the diagnostic criteria for PTSD.

Calling any treatment a Magic Bullet is a misnomer, but after the impressive results in Phase 2 trials, the FDA gave MDMA-assisted psychotherapy its Breakthrough Therapy Designation.

According to the FDA’s official FAQ section…

breakthrough therapy designation is for a drug that treats a serious or life-threatening condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement on a clinically significant endpoint(s) over available therapies.

MAPS is beginning their Phase 3 trials now, the final phase before the FDA decides whether or not MDMA can be prescribed legally as a treatment for PTSD. Assuming the newest trials go as well as the previous ones, MDMA-assisted psychotherapy could be available as a treatment option for PTSD within the next two years.

If that happens, many people with treatment-resistant PTSD might find a way out of their personal hell by combining therapy with a chemical that’s been said to “feel like Heaven.”